Identification and characterization of aminopeptidases from Aplysia californica.
Aminopeptidase activities were identified in extracts of kidney, ovotestis, head ganglia, heart and haemolymph of Aplysia californica. These enzyme preparations hydrolysed [3H][Leu]enkephalin at the Try-1-Gly-2 bond as determined by h.p.l.c. analysis of cleavage products. In all these tissues, enkephalin-degrading aminopeptidase activities were present both in membrane-bound and cytosolic fractions. The bivalent-cation-chelating agent, 1,10-phenanthroline, inhibited kidney membrane aminopeptidase activity with an IC50 of 30 microM, suggesting that this enzyme is a metalloproteinase. The aminopeptidase inhibitor amastatin was the most potent inhibitor of [Leu]enkephalin degradation (IC50 25 nM) by membrane-bound aminopeptidase, and bacitracin, bestatin and puromycin were about 100-1000 times less potent. In contrast with membrane-bound aminopeptidase, the cytosolic form is sensitive to puromycin. Angiotensin-converting enzyme inhibitor had no effect on [Leu]enkephalin degradation by kidney membranes, while the neutral endopeptidase inhibitors were poor inhibitors of the enzymes in this preparation. The Km values of the aminopeptidase in the kidney membranes and cytosolic fractions for the [Leu]enkephalin substrate were 2.4 and 7.4 microM respectively. The aminopeptidase present in the kidney membranes also hydrolysed endogenous Phe-Met-Arg-Phe-amide peptide at the Phe-1-Met-2 bond as well as synthetic alanine p-nitroanilide and leucine p-nitroanilide. When used in a competition assay, these substrates inhibited hydrolysis of [3H][Leu]enkephalin, suggesting that the same enzyme degraded all these substrates. Taken together, these results suggest that Aplysia tissues contain both a membrane-bound aminopeptidase related to the mammalian aminopeptidase N and a cytosolic puromycin-sensitive aminopeptidase.
Bawab
W
W
Department of Biochemistry, University of Montreal, Quebec, Canada.
Querido
E
E
Crine
P
P
DesGroseillers
L
L
D000626:Aminopeptidases / Q000037:antagonists & inhibitors / Q000302:isolation & purification* / Q000378:metabolism; D000813:Anilides / Q000378:metabolism; D000814:Aniline Compounds / Q000378:metabolism; D000818:Animals; D000900:Anti-Bacterial Agents; D001048:Aplysia / Q000201:enzymology*; D001414:Bacitracin / Q000494:pharmacology; D002851:Chromatography, High Pressure Liquid; D004743:Enkephalin, Leucine / Q000378:metabolism; D019835:FMRFamide; D005724:Ganglia / Q000201:enzymology; D006458:Hemolymph / Q000201:enzymology; D007668:Kidney / Q000201:enzymology; D007930:Leucine / Q000031:analogs & derivatives / Q000494:pharmacology; D008297:Male; D009206:Myocardium / Q000201:enzymology; D009479:Neuropeptides / Q000378:metabolism; D009842:Oligopeptides / Q000494:pharmacology; D010057:Oviducts / Q000201:enzymology; D010455:Peptides; D011691:Puromycin / Q000494:pharmacology; D013737:Testis / Q000201:enzymology
D000813:Anilides; D000814:Aniline Compounds; D000900:Anti-Bacterial Agents; D009479:Neuropeptides; D009842:Oligopeptides; D010455:Peptides; D001414:Bacitracin; C004813:alanine-4-nitroanilide; D011691:Puromycin; D004743:Enkephalin, Leucine; D019835:FMRFamide; C001536:1-leucine-4-nitroanilide; C016977:amastatin; D000626:Aminopeptidases; D007930:Leucine; C012211:ubenimex